行情

INM

INM

InMed Pharmaceuticals Inc.
NASDAQ

实时行情|Nasdaq Last Sale

1.470
-0.020
-1.34%
盘后: 1.540 +0.07 +4.76% 18:45 12/03 EST
开盘
1.570
昨收
1.490
最高
1.650
最低
1.440
成交量
152.16万
成交额
--
52周最高
6.42
52周最低
1.255
市值
2,078.14万
市盈率(TTM)
-1.0273
分时
5日
1月
3月
1年
5年
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs
InMed Pharmaceuticals (NASDAQ: INM) recently filed a Patent Cooperation Treaty (“PCT”) application, which specifies a rare cannabinoid (new to InMed’s portfolio) that may inhibit or slow the progression of neurogenerative diseases – such as...
Investor Brand Network · 4天前
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021
 
Benzinga · 5天前
InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs
For the three months ending September 30, 2021 (“Q1 2022”), InMed Pharmaceuticals (NASDAQ: INM), a global leader in pharmaceutical development, manufacturing, and commercialization of rare cannabinoids, witnessed positive momentum across all of...
Investor Brand Network · 5天前
CODX, SM and PERI among pre market gainers
Krystal Biotech KRYS +115% says study on VYJUVEKTM for rare skin disease met primary endpoint Petros Pharmaceuticals PTPI +62% 180 Life Sciences, Vaxart gain amid social media buzz; Petros climb over 60% NRx Pharmaceuticals
Seekingalpha · 5天前
HC Wainwright & Co. Initiates Coverage On InMed Pharmaceuticals with Buy Rating, Announces Price Target of $6
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on InMed Pharmaceuticals (NASDAQ:INM) with a Buy rating and announces Price Target of $6.
Benzinga · 5天前
InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Upcoming Cannabis Conference
InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, will be participating in the 4th annual Cowen Cannabis Conference. InMed’s management team will be presenting in the...
Investor Brand Network · 11/23 14:56
InMed Pharmaceuticals to Participate in Cowen’s 4th Annual Cannabis Conference
VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the...
Globe Newswire · 11/23 12:30
Welcome to the Party $INM! Competition or Compliment to $SNDL? — Cannabis Daily November 18, 2021
The Best Daily Overview Of The Cannabis Space South Dakota lawmakers recommend bill to legalize marijuana. New York bans advertising for cannabis and psychedelics in subways. Rep. Nancy Mace's history with cannabis. In today's episode we covered the follow...
Benzinga · 11/18 19:30
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解INM最新的财务预测,通过INM每股收益,每股净资产,每股现金流等数据分析InMed Pharmaceuticals Inc.近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
100.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测INM价格均价为6.75,最高价位7.50,最低价为6.00。
最高7.50
均价6.75
最低6.00
现价1.470
EPS
实际EPS
预期EPS
-0.33-0.25-0.16-0.08
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
机构持股
总机构数: 18
机构持股: 55.97万
持股比例: 3.96%
总股本: 1,413.70万
类型机构数股数
增持
3
5,463
建仓
2
1.14万
减持
2
38.08万
平仓
3
2.08万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-2.46%
制药与医学研究
-0.60%
高管信息
Chairman/Independent Director
William Garner
President/Chief Executive Officer/Director
Eric Adams
Chief Financial Officer/Secretary
Bruce Colwill
Senior Vice President
Eric Hsu
Senior Vice President
Alexandra Mancini
Vice President
Michael Woudenberg
Independent Director
Adam Cutler
Independent Director
Andrew Hull
Independent Director
Catherine Sazdanoff
暂无数据
INM 简况
InMed Pharmaceuticals Inc. is a clinical stage pharmaceutical company that is engaged in the development, manufacturing and commercialization of rare cannabinoids. The Company is developing a pipeline of prescription-based products targeting treatments for diseases with unmet medical needs as well as developing manufacturing technologies. It is specializing in the research and development of cannabinoid-based therapies and a system for the manufacturing of pharmaceutical-grade cannabinoids. It is also developing an integrated biosynthesis-based manufacturing approach, called IntegraSyn, for synthesizing pharmaceutical-grade cannabinoids, for potential use in product candidates. The Company's two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 provides direct neuroprotection and reduce intraocular pressure in the eye.

微牛提供InMed Pharmaceuticals Inc(NASDAQ-INM)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的INM股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易INM股票基本功能。